Quantum BioPharma received FDA clearance to move its investigational drug Lucid‑MS, also known as Lucid‑21‑302, into a phase 2 trial for progressive multiple sclerosis, marking a rare step toward a therapy that targets demyelination directly.
Phase 2 trial design and leadership
The upcoming study will be a randomized, double‑blind, placebo‑controlled trial that aims to assess efficacy, safety, and tolerability using both clinical and radiological outcomes linked to disability progression. Patient enrollment is expected to begin as soon as site selection and other start‑up activities are finalized.
Quantum BioPharma has partnered with a clinical research organization to manage trial implementation. The company announced Salvatore Napoli, MD, president and medical director of the Neurology Center of New England and the MS Center of New England, as the principal investigator. “The randomized, double‑blind, placebo‑controlled Phase 2 trial is intended to evaluate efficacy using clinical and radiological measures relevant to disability progression and disease biology, while also assessing safety and tolerability,” said Andrzej Chruscinski, MD, PhD, vice president of scientific and clinical affairs.
Related: User Blocked After Repeated Policy Violations
Background and mechanism of Lucid‑MS
Lucid‑MS is a non‑covalent inhibitor of protein arginine deiminase 2 (PAD2), an enzyme that catalyzes citrullination of myelin proteins in the central nervous system. Unlike most approved MS drugs that modulate immune activity, Lucid‑MS is intended to act directly on the demyelination pathway, and preclinical models have suggested it can prevent and even reverse myelin loss.
The IND filing drew on data from a phase 1 multiple ascending‑dose trial involving 40 healthy volunteers aged 18 to 60. Participants received daily oral doses of 150 mg or 300 mg of Lucid‑21‑302 for seven days, or placebo. The study reported 38 treatment‑emergent adverse events across 12 participants, most of which were mild and none were judged related to the investigational drug. Pharmacokinetic analysis showed dose‑proportional exposure, with area‑under‑the‑curve values rising from roughly 4.2‑5.3 hr·µg/mL at the lower dose to 9.8‑11.6 hr·µg/mL at the higher dose.
Earlier, the company completed 180‑day repeated‑dose oral toxicity and toxicokinetic studies in late 2025, providing additional safety data that supported the IND application and helped shape the phase 2 design.
In the broader field, no FDA‑approved therapy has yet demonstrated true remyelinating or demyelination‑preventing effects. Recent attempts, such as Contineum Therapeutics’ PIPE‑307 and Biogen’s opicinumab, have faltered in phase 2 trials, highlighting the difficulty of achieving meaningful clinical benefit through this approach.
Related: User blocked after policy violation
Compared with earlier setbacks, the current effort feels like cautious optimism. While earlier candidates stumbled at the placebo comparison stage, Lucid‑MS’s preclinical data and early human safety profile give it a slightly stronger footing, though the trial’s outcome will still hinge on whether those laboratory signals translate into real‑world improvement.
Next steps and expectations
The trial will enroll participants with progressive MS, a form of the disease that currently has limited treatment options. Researchers will monitor participants for changes in disability measures, MRI‑based markers of myelin integrity, and any adverse events over the study period. Results are expected to inform whether Lucid‑MS can move into larger, possibly critical, studies.
Quantum BioPharma’s filing notes that the phase 2 design was informed by both the phase 1 safety profile and the toxicology work completed the previous year. If the trial demonstrates a favorable risk‑benefit balance, the company may pursue additional indications or broader patient populations.